With 2.97 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.21 million shares. The 52-week range on GENI shows that it touched its highest point at $11.40 and its lowest point at $5.03 during that stretch. It currently has a 1-year price target of $12.40. Beta for the stock currently stands at 1.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GENI was down-trending over the past week, with a drop of -2.81%, but this was down by -2.90% over a month. Three-month performance surged to 1.21% while six-month performance rose 4.59%. The stock gained 84.04% in the past year, while it has gained 15.95% so far this year. A look at the trailing 12-month EPS for GENI yields -0.20 with Next year EPS estimates of 0.13. For the next quarter, that number is 0.01. This implies an EPS growth rate of 105.29% for this year and 776.20% for next year.
Float and Shares Shorts:
At present, 239.82 million GENI shares are outstanding with a float of 216.07 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GENI since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.13852 being high and -$0.14333 being low. For GENI, this leads to a yearly average estimate of -$0.14082.
